The estimated Net Worth of Robert J Kammer is at least $34.2 Million dollars as of 11 November 2019. Robert Kammer owns over 6,500 units of Harrow Health stock worth over $32,985,418 and over the last 8 years he sold HROW stock worth over $1,099,255. In addition, he makes $151,500 as Independent Chairman of the Board at Harrow Health.
Robert has made over 17 trades of the Harrow Health stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 6,500 units of HROW stock worth $30,875 on 11 November 2019.
The largest trade he's ever made was selling 130,000 units of Harrow Health stock on 10 August 2018 worth over $390,000. On average, Robert trades about 10,900 units every 34 days since 2016. As of 11 November 2019 he still owns at least 797,327 units of Harrow Health stock.
You can see the complete history of Robert Kammer stock trades at the bottom of the page.
Dr. Robert J. Kammer serves as Independent Chairman of the Board of the Company. In June 2014, Dr. Kammer joined the board of directors of SoftScience Shoe Company as the co-chairman. In January 2015, Dr. Kammer retired from his clinical practice as a dentist, in which he was engaged from 1975 to 2015. He is a retired Diplomate of The American Board of Orofacial Pain and a Founding Member of The Academy for Sports Dentistry and Colorado Osseointegration Study Club. From 1979 to 1996, Dr. Kammer was an Associate Professor at the University of Colorado School of Dental Medicine. Dr. Kammer has also served as a consultant to the Boulder-Denver Pain Control Center and a reviewer for the Journal of Orofacial Pain. Dr. Kammer recently contributed a chapter to the text “Osteoperiosteal Flap”, has co-authored multiple scientific articles, was co-investigator on a Dental Implant Bar Study at the Mayo Institute from 2011 to 2013 and served as a consultant for Clear Choice Dental Implant Centers from 2010 to 2013. Dr. Kammer received his Bachelor of Science degree in 1971 from Xavier University, Cincinnati, Ohio. He received his Doctor of Dental Surgery degree from the University of Iowa College of Dentistry in 1974. Dr. Kammer brings to our Board over 35 years of clinical experience treating patients and leadership experience in a variety of positions.
As the Independent Chairman of the Board of Harrow Health, the total compensation of Robert Kammer at Harrow Health is $151,500. There are 7 executives at Harrow Health getting paid more, with Mark Baum having the highest compensation of $1,377,010.
Robert Kammer is 70, he's been the Independent Chairman of the Board of Harrow Health since 2012. There are 2 older and 9 younger executives at Harrow Health. The oldest executive at Harrow Health, Inc. is Dr. Robert J. Kammer D.D.S., 72, who is the Special Advisor.
Robert's mailing address filed with the SEC is C/O HARROW HEALTH, INC., 102 WOODMONT BLVD. SUITE 610, NASHVILLE, TN, 37205.
Over the last 6 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock and bought 1,487,560 units worth $12,882,479 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum, and Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of $3,323,914. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth $199,400.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Harrow Health executives and other stock owners filed with the SEC include: